Valuation: BELLUS Health

Market Cap 1.86B 1.66B 1.55B 1.41B 2.66B 180B 2.68B 18.73B 7.29B 91.67B 7B 6.85B 295B P/E 2021
-8.95x
P/E 2022 -12.4x
Enterprise Value 1.53B 1.36B 1.27B 1.16B 2.18B 147B 2.19B 15.36B 5.97B 75.16B 5.74B 5.62B 242B EV / Sales 2021
36,416x
EV / Sales 2022 43,771x
Free-Float
81.52%
Yield 2021 *
-
Yield 2022 -
5 years 6.3
Extreme 6.3
19.9
10 years 0.76
Extreme 0.756
19.9
Manager TitleAgeSince
President - 2023-05-31
Director of Finance/CFO 53 2020-12-06
Chief Tech/Sci/R&D Officer 69 2009-12-31
Director TitleAgeSince
Chairman 79 2001-12-31
Director/Board Member 54 2009-05-31
Director/Board Member 80 2009-05-31
Date Insider Type Main position Quantity % Market Cap. Importance
6/29/23 OtherCompany 0 0% -
6/22/23 Option

Director

27,777 0.0219%
6/22/23 Option

Executive/Senior Manager

75,000 0.0593%
Change 5-day change 1-year change 3-year change Capi.($)
-0.10%-.--%-.--%-.--% 1.87B
+4.16%+3.04%+49.37%+94.17% 74.16B
-0.37%-3.81%+19.51%+78.12% 57.39B
+1.63%-1.61%+3.16%+36.89% 47.64B
+0.74%+3.49%+348.24%+726.56% 44.29B
+2.20%-2.75%+28.54%+33.21% 42.5B
+0.59%-1.70%+4.71%+111.38% 40.71B
-0.54%+2.93%+9.31%+54.06% 30.97B
+1.56%+4.53%+31.34%+26.92% 28.53B
+0.88%-1.48%-7.18%-11.14% 24.34B
Average +1.04%-0.49%+48.70%+115.02% 39.24B
Weighted average by Cap. +1.40%-0.83%+58.02%+136.40%

Financials

2021 2022
Net sales 16K 14.27K 13.3K 12.1K 22.79K 1.54M 22.96K 161K 62.52K 786K 60.06K 58.77K 2.53M 16K 14.27K 13.3K 12.1K 22.79K 1.54M 22.96K 161K 62.52K 786K 60.06K 58.77K 2.53M
Net income -71.22M -63.54M -59.2M -53.87M -101M -6.86B -102M -715M -278M -3.5B -267M -262M -11.25B -76.08M -67.87M -63.23M -57.54M -108M -7.33B -109M -764M -297M -3.74B -286M -279M -12.02B
Net Debt -248M -221M -206M -188M -353M -23.88B -356M -2.49B -969M -12.19B -931M -911M -39.17B -336M -300M -279M -254M -478M -32.34B -482M -3.37B -1.31B -16.5B -1.26B -1.23B -53.05B
Logo BELLUS Health
BELLUS Health Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the lives of patients suffering from persistent cough, starting with the development of camlipixant (BLU-5937) for the treatment of refractory chronic cough (RCC). Camlipixant is a highly selective antagonist of the P2X3 receptor, a clinically validated target to treat cough hypersensitivity. It is being evaluated in the CALM phase III clinical development programmed. It is developing camlipixant for the treatment of adults with RCC. Camlipixant has the potential to address the significant unmet need for an efficacious, safe and well tolerated treatment for refractory chronic cough.
Employees
74